Alnylam Pharmaceuticals
Develops and commercializes RNAi medicines led by the AMVUTTRA-centered TTR franchise.
$240.00
After-hours close+2.90 (+1.22%)
At close$237.10(+0.23%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 145.06%Insiders 0.24%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 133.81M · Float 133.23M · 99.6% free float
Institutions13F, as of Jun 30, 2026
824 holders · 194.10M shares · 91 new positions · 412 increased · 283 reduced · 94 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 15.02M | 11.23% | +444.8K | Aug 13, 2026 |
| Capital World Investors | 11.14M | 8.33% | +342.5K | Aug 12, 2026 |
| BlackRock, Inc. | 10.91M | 8.15% | +462.8K | Aug 7, 2026 |
| Capital Research Global Investors | 9.75M | 7.29% | +279.5K | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 6.54M | 4.89% | +47.1K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.03M | 4.51% | +82.8K | Aug 13, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.64M | 4.22% | +448.8K | Aug 14, 2026 |
| Invesco Ltd. | 3.75M | 2.81% | +970.9K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 11.00% | 14.64M | 13G | May 6, 2026 ↗ |
| Capital World Investors | 8.20% | 10.92M | 13G | May 14, 2026 ↗ |
| Capital Research Global Investors | 7.10% | 9.47M | 13G | May 14, 2026 ↗ |
| Vanguard Capital Management | 5.35% | 7.10M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Yvonne Greenstreet | director, officer: Chief Executive Officer | 95.7K | 0.07% | Mar 6, 2026 |
| Jeffrey V. Poulton | officer: EVP, Chief Financial Officer | 61.8K | 0.05% | Mar 6, 2026 |
| Tolga Tanguler | officer: EVP, Chief Commercial Officer | 34.3K | 0.03% | Mar 6, 2026 |
| Amy W. Schulman | director | 24.0K | 0.02% | May 22, 2026 |
| Kevin Joseph Fitzgerald | officer: CSO & EVP, Head of Research | 20.6K | 0.02% | Mar 6, 2026 |
| Pushkal Garg | officer: EVP Chief R&D | 18.7K | 0.01% | Mar 6, 2026 |
| Michael W. Bonney | director | 16.8K | 0.01% | Aug 19, 2025 |
| Bryan Supran | officer: EVP, CLO and Secretary | 14.6K | 0.01% | Mar 4, 2026 |
| Melissa McLaughlin | officer: Chief Human Resources Officer | 9.4K | 0.01% | Apr 7, 2026 |
| Robert W. Hesslein | officer: EVP, CLO and Secretary | 8.0K | 0.01% | Mar 5, 2025 |
11 ten-percent owners hold 16.01M shares by Form 4, outside the officers-and-directors figure above · 14 people have not refiled in the last 18 months (397.3K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 1, 2026 | David E. I. Pyottdirector | Sale · 5 lots | 3,830 | $299.18 | 1,582 |
| Apr 6, 2026 | Melissa McLaughlinofficer: Chief Human Resources Officer | Sale · 5 lots | 2,286 | $330.42 | 9,443 |
| Apr 2, 2026 | Melissa McLaughlinofficer: Chief Human Resources Officer | Sale · 9 lots | 1,624 | $319.59 | 11,729 |
| Mar 5, 2026 | Kevin Joseph Fitzgeraldofficer: CSO & EVP, Head of Research | Sale · 4 lots | 658 | $323.98 | 20,569 |
| Mar 4, 2026 | Kevin Joseph Fitzgeraldofficer: CSO & EVP, Head of Research | Sale · 8 lots | 633 | $323.08 | 21,227 |
| Mar 4, 2026 | Tolga Tangulerofficer: EVP, Chief Commercial Officer | Sale · 8 lots | 2,309 | $323.08 | 34,297 |
| Mar 4, 2026 | Jeffrey V. Poultonofficer: EVP, Chief Financial Officer | Sale · 8 lots | 2,468 | $323.08 | 61,805 |
| Mar 4, 2026 | Yvonne Greenstreetdirector, officer: Chief Executive Officer | Sale · 8 lots | 2,933 | $323.08 | 95,695 |
| Mar 5, 2026 | Pushkal Gargofficer: EVP Chief R&D | Sale · 4 lots | 2,404 | $323.96 | 18,693 |
| Mar 4, 2026 | Pushkal Gargofficer: EVP Chief R&D | Sale · 8 lots | 2,309 | $323.08 | 21,097 |
CongressHouse and Senate disclosures
Not reported.